TECHNOLOGY & PRODUCTS

Vaccine Technology

GeoVax, Inc. HIV/AIDS [HIV-1] Vaccines, initially developed by Dr. Harriet Robinson [GeoVax Scientific Advisory Board Chairperson] at Emory University in collaboration with researchers at the NIAID (NIH), and the USA Centers for Disease Control (CDC), are recombinant DNA and MVA vaccines. Our focus is on developing AIDS vaccines comprising the major HIV-1 subtypes (A, B and C). These vaccines will be able to be used alone or as combinations depending on a local infection. Subtype B is most common in North America, the EU, Japan and Australia and is our first priority.

When administered in series, these AIDS vaccines induce strong cellular and humoral immunity [protection] in non human primates against multiple HIV-1 proteins [AIDS virus components]. This suggests that GeoVax's vaccines will provide protection against the development of AIDS in HIV-1 virus infected people.

Our Progress

  • Excellent Preclinical Data Demonstrating 96% Protection
  • Phase 1 Human Trial of a prototype DNA Completed & Satisfactory
  • Phase 1A/IB Human Trials Combining DNA with MVA and Testing Different Regimens - Started in April 2006, September 2006, and two in June 2007.
  • Phase 2 Human Trial in Planning Stage for 2008